Opioid Antagonists for Use in Patients Using Chimeric Antigen Receptor T and NK Cell Therapy

Case ID:
C16410

Unmet Need

Cancer patients often experience extreme, chronic pain that is addressed through prescription opioids. These opioids can block receptors on NK and T cells, resulting in a reduced ability to initiate apoptosis and therefore a reduced immune response. This, combined with other factors including the cancer itself, chemotherapy and radiation treatments further compromises the immune systems of patients. Therefore, cancer patients need a way to effectively manage pain through opioids without reducing their immune responses.

Technology Overview

Researchers at Johns Hopkins University have found that opioids can inhibit the ability of T and NK cells to induce apoptosis, and have proposed a gene therapy treatment to address this problem. Through targeting and manipulation of the OPRM, ORPK, OPRD and OPRL genes, the impact on the T and NK cells can be reduced or eliminated, therefore reinstating the immune function of patients.

Stage of Development

This discovery is still in the early stage. Researchers have shown how the opioids impact the T and NK cells, and have identified some genes which can be targeted to reduce this impact. The genetic modification of these genes in T and NK cells is the next step to show the efficacy of the treatment.

Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
OPIOID ANTAGONISTS FOR USE IN PATIENTS USING CHIMERIC ANTIGEN RECEPTOR T AND NATURAL KILLER (NK) CELL THERAPY ORD: Ordinary Utility United States 17/508,673   10/22/2021     Pending
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Michael Woods
mwoods19@jh.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum